L
inezolid is an oxazolidinone antimicrobial useful in the treatment of gram-positive infections including organisms resistant to several other antimicrobials. 1 Resistance to linezolid is rare, and has recently been summarized. The antimicrobial is hypothesized to inhibit protein synthesis by binding to the domain V region of 23S rRNA.
2 Several mutations in this area can confer resistance in vitro.
2-5 Specifically, G to U mutations at position 2576 of the 23S rRNA have been reported in clinical isolates of Enterococcus faecium, 6, 7 Enterococcus faecalis, 7 and Staphylococcus aureus. 3 Resistant isolates of Staphylococcus epidermidis and Streptococcus oralis, 8 described in this issue by Mutnick et al., 10 also have been found to contain a G2576U mutation (among other mutations). Mutation in the 23S rRNA at position 2247 has conferred resistance in pneumococci.
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In this issue, Mutnick et al. present data from the SEN-TRY Antimicrobial Surveillance Program documenting linezolid resistance in their US database. Although the rate of resistance was a mere 8 of 9833 isolates (0.08%), the resistant isolates were obtained from 6 different states, 7 different hospitals, and in 5 patients without exposure to the antimicrobial. The organisms involved included 1 isolate each of S. oralis and S. epidermidis. Resistance in clinical isolates of these organisms has not been previously reported. The isolates presented include a patient with a linezolid-resistant E. faecium blood culture isolate, not associated with prior treatment, whose case has been detailed elsewhere. 11 The surveillance data in this issue do not provide information about antimicrobial usage patterns, endemic resistance issues, or infection control practices at SEN-TRY-participating institutions. The authors conclude with a recommendation for routine monitoring of linezolid susceptibility among gram-positive pathogens. Surveillance for resistance is desirable to provide local data for selection of empiric therapy, to assess the magnitude of problems at various geographic levels, to monitor for susceptibility changes, and to detect the emergence of new resistance.
12 Limitations always include bias and error related to collection, storage, and transportation issues, standardization of testing methods, and the variability of patients from whom samples are sent for testing. 11 The SENTRY surveillance network is a well-established surveillance database originally designed to assess susceptibility changes over a 5-to 10-year period. It has evolved from approximately 30 institutions to >80 sites today and offers an important benchmark for regional, national, and international data.
How do we assess the importance of 0.08% resistance identified through a national surveillance system? The answer is multifactorial, depending on several issues. It is useful to know whether the data are diluted by institutions that do not use linezolid or magnified by those that overuse it. Most useful to clinicians would be data from institutions with comparable patient demographics, antimicrobial usage patterns, and geographic location. However, data this specific are often unavailable. Information on a national level, such as those provided by Mutnick et al., can provide a large enough sampling to identify emerging resistance problems. It is also important to assess the overall trend of resistance over time. The incidence of resistant isolates can increase rapidly or slowly over time (similar to penicillin resistance in pneumococcus, which developed over several decades). The minimum inhibitory concentration (MIC) distribution from the new SENTRY data is similar to what has been previously reported, 13 implying that a generalized and gradual shift to higher MICs has not been identified. However, since linezolid has only been available in the US since 2000, a longer assessment period may be required for such a judgment.
It is also of interest to know the natural mutation rate of isolates and the selective influence of antimicrobials. Organisms undergo spontaneous mutational events. Some of these mutations may confer resistance in future organisms. The frequency of spontaneous target site mutation is thought to be very low when gram-positive organisms are exposed to low concentrations of linezolid. For S. aureus, the frequency is estimated to be <10
.
2,4 This would explain the rare incidence of nonsusceptible clinical isolates of this organism. Linezolid resistance develops more readily in vitro to enterococci.
14 Animal models suggest that resistance is more easily induced in vivo than in vitro whether testing pneumococci, methicillin-susceptible S. aureus or methicillin-resistant S. aureus (MRSA) isolates.
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Data attributing increased linezolid use to a rise in clinical resistance in humans are scant. In one cohort of patients, a rapid decrease in vancomycin-resistant E. faecium susceptibility to linezolid, from 100% to 80% of blood culture isolates, occurred at MD Anderson Cancer Center in Houston soon after the addition of linezolid to their formulary. 16 Resistance to linezolid has occurred most often as a result of selective pressure after prolonged treatment courses or via nosocomial spread to other patients. Herrero et al. 6 reported a clonal outbreak of linezolid-resistant E. faecium from 7 patients within a single institution. The strain first appeared in a patient who had been treated with linezolid. Despite the exclusive availability of private rooms and the requirement to wear gloves on this patient's ward, the organism was transmitted to other patients who had not received linezolid.
While the emergence of linezolid resistance due to selective pressure in the index patient was of concern, the spread of the multidrug resistant-organism to other patients was more alarming. In the UK, the first 3 linezolid-resistant clinical isolates of E. faecium (n = 2) and E. faecalis (n = 1) have recently been described. 7 Pulsefield gel electrophoresis analysis and sequence analysis of rRNA demonstrated resistance that developed in previously susceptible strains. All patients were receiving linezolid at the time of culture isolation, suggesting selective pressure. The isolation of vancomycin-susceptible but linezolid-resistant E. faecalis in patients previously treated with linezolid-or ampicillin-susceptible vancomycin-resistant E. faecium suggests that resistance in enterococci may occur independently of vancomycin or ampicillin susceptibility. 17 These data suggest that resistance can occur in the absence of exposure, via transmission from another patient or external source, incidental surveillance capture of a naturally occurring mutation event, or selection of a resistant subpopulation present in the original population of organisms tested. This is probably true for other gram-positive organisms.
Resistance of S. aureus to linezolid is less common. The first clinical isolate of S. aureus resistant to linezolid was described in an 85-year-old man undergoing peritoneal dialysis who developed peritonitis caused by MRSA. 3 The dialysis catheter was not removed during a prolonged course of oral treatment with linezolid 600 mg every 12 hours. The stability and growth characteristics of this isolate were assessed and found to be similar to comparison strains.
2 A second patient developed linezolid-resistant MRSA from a susceptible isolate during prolonged linezolid treatment. 5 As with enterococci, the mutation appeared to be stable, not to impair the organism's metabolic function, and may be able to disseminate without continued selective pressure.
2
Resistance trends identified by surveillance screening usually find the highest incidence of resistance in hospitalized patients, particularly those in intensive care units.
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However, the resistance described by Mutnick et al. occurred in multiple institutions and in several states. This should alarm all practitioners. Are we surprised by resistance developing to linezolid? No. Should we be looking for it ? Yes. The incidence of resistance may represent a harbinger of things to come or a temporary "blip." Given the history of antimicrobial usage and resistance, the former scenario is more likely.
What should we do to quantify and curb emerging resistance to linezolid? Prudent use and susceptibility testing are recommended. Surveillance based on routine susceptibility testing uses an already ongoing extensive data collection. 12 However, it is not uncommon to identify several hundred isolates of gram-positive organisms per year from a single institution. To test all of these isolates for linezolid susceptibility seems impractical. Perhaps a reasonable approach would be to recommend frequent testing only in institutions extensively using linezolid. Pharmacists often help draft antimicrobial guidelines and are involved with identifying patients who are candidates for linezolid therapy or who are failing treatment. Pharmacists would also be instrumental in determining and defining when usage increases to a point that warrants more frequent testing. Susceptibility testing may be of most interest in patients prescribed or failing the antimicrobial. This policy of limited testing would be advisable in institutions severely restricting this antimicrobial.
Others have also suggested a limited susceptibility testing strategy for linezolid.
7,11 Albany Medical Center Hospital is a 620-bed tertiary care institution that restricts linezolid use to documented vancomycin-resistant enterocci infections. In 2002, our Department of Microbiology identified 2332 different patients with positive cultures for either Staphylococcus spp., Streptococcus pneumoniae, or Enterococcus spp. The number of these isolates tested for linezolid susceptibility is not known. However, our institution has chosen not to routinely test all gram-positive isolates for linezolid susceptibility. Tests are requested by physicians or clinical pharmacists on an individual basis when patients are prescribed or are failing therapy with this oxazolidinone. In the first 2 months of this year, 14 patients were prescribed linezolid. We identified linezolid use to be increasing and occasionally outside of our formulary restriction. While we are attempting to limit empiric and nonindicated use of linezolid, we do not plan to increase susceptibility testing at this time. The decision on how fre- quently to test for linezolid susceptibility will vary with each institution depending on baseline resistance patterns, use of this antimicrobial, and tolerance to potentially missing a (rarely) resistant isolate. Our institution will not adopt blanket testing for linezolid susceptibility of all gram-positive isolates based on the current level of resistance. Pharmacists can also assist in interpreting MICs for linezolid. The MICs typically range between 1 and 4 µg/mL for staphylococci, 1-2 µg/mL for enterococci, and 0.5 and 1.0 µg/mL for streptococci. 19 An MIC ≤4 µg/mL indicates susceptibility; ≥8 µg/mL implies a mutational resistance to this oxazolidinone. 11 Isolates with MICs ≥8 µg/mL are rare and should be referred to the manufacturer or a reference laboratory for confirmation. 19 There should also be procedures established for confirmation and referral of resistant isolates similar to those used for vancomycin-intermediate S. aureus.
In conclusion, multidisciplinary efforts that include adequate infection control policies are often the most effective options to minimize endemic resistance. 18 The best approach to limiting linezolid resistance is multifactorial. Pharmacists and other infectious diseases practitioners play a key role in the appropriate selection of patients prescribed linezolid and in ensuring proper dosage, frequency, and treatment duration. Infection control efforts are also required to minimize cross-transmission of resistant isolates passed from patient to patient. Certain risk factors, such as indwelling catheters and prolonged hospitalization, may be difficult to avoid. However, given the widespread and often inappropriate use of antimicrobials, pharmacists continue to play a central role in the prudent use of these agents.
2,7
On December 20, 2002, the Food and Drug Administration announced the approval of linezolid injection, tablets, and oral suspension for the treatment of selected gram-positive infections in infants and children. The implications for resistance resulting from broader use of this antimicrobial remain to be seen. The work of surveillance systems such as SENTRY will be invaluable in this regard.
How hard should we look for resistance to this oxazolidinone? Based on the current levels of resistance, my recommendation would be to test susceptibility in patients prescribed or failing linezolid therapy.
